284 related articles for article (PubMed ID: 14972474)
1. Epididymitis after prostate brachytherapy.
Hoffelt SC; Wallner K; Merrick G
Urology; 2004 Feb; 63(2):293-6. PubMed ID: 14972474
[TBL] [Abstract][Full Text] [Related]
2. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
[TBL] [Abstract][Full Text] [Related]
3. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
[TBL] [Abstract][Full Text] [Related]
5. Factors predicting for urinary incontinence after prostate brachytherapy.
McElveen TL; Waterman FM; Kim H; Dicker AP
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
[TBL] [Abstract][Full Text] [Related]
6. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy.
Gutman S; Merrick GS; Butler WM; Wallner KE; Allen Z; Galbreath RW; Adamovich E
BJU Int; 2006 Jan; 97(1):62-8. PubMed ID: 16336330
[TBL] [Abstract][Full Text] [Related]
7. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
[TBL] [Abstract][Full Text] [Related]
8. Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy.
Williams SG; Millar JL; Duchesne GM; Dally MJ; Royce PL; Snow RM
Radiother Oncol; 2004 Oct; 73(1):33-8. PubMed ID: 15465143
[TBL] [Abstract][Full Text] [Related]
9. Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer.
Sherertz T; Wallner K; Merrick G; Ford E; Sutlief S; Cavanagh W; Butler W; True L
Brachytherapy; 2004; 3(3):130-5. PubMed ID: 15533804
[TBL] [Abstract][Full Text] [Related]
10. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Murray B; Allen Z; Lief JH; Galbreath RW
Brachytherapy; 2004; 3(1):22-9. PubMed ID: 15110310
[TBL] [Abstract][Full Text] [Related]
11. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
Lee HK; Adams MT; Motta J
Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
[TBL] [Abstract][Full Text] [Related]
12. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
Hurwitz MD; Halabi S; Ou SS; McGinnis LS; Keuttel MR; Dibiase SJ; Small EJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):814-9. PubMed ID: 18407435
[TBL] [Abstract][Full Text] [Related]
13. Epididymitis after transrectal ultrasound-guided needle biopsy of prostate gland.
Donzella JG; Merrick GS; Lindert DJ; Andreini HJ; Curtis RL; Luna IH; Allen Z; Butler WM
Urology; 2004 Feb; 63(2):306-8. PubMed ID: 14972477
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy.
Schwartz DJ; Schild SE; Wong WW; Vora SA
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):60-3. PubMed ID: 15629594
[TBL] [Abstract][Full Text] [Related]
15. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials.
Ghaly M; Wallner K; Merrick G; True L; Sutlief S; Cavanagh W; Butler W
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1288-93. PubMed ID: 12654439
[TBL] [Abstract][Full Text] [Related]
16. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial.
Herstein A; Wallner K; Merrick G; Mitsuyama H; Armstrong J; True L; Cavanagh W; Butler W
Cancer J; 2005; 11(5):385-9. PubMed ID: 16259869
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study.
Elshaikh MA; Ulchaker JC; Reddy CA; Angermeier KW; Klein EA; Chehade N; Altman A; Ciezki JP
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):164-9. PubMed ID: 15850917
[TBL] [Abstract][Full Text] [Related]
18. Incidence and clinical course of hemorrhagic radiation proctitis after iodine-125 prostate brachytherapy.
Mishra MV; Shirazi R; Barrett WL
Clin Genitourin Cancer; 2007 Sep; 5(6):397-400. PubMed ID: 17956713
[TBL] [Abstract][Full Text] [Related]
19. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
[TBL] [Abstract][Full Text] [Related]
20. Radiation safety aspects of brachytherapy for prostate cancer using permanently implanted sources. A report of ICRP Publication 98.
International Commission on Radiological Protection
Ann ICRP; 2005; 35(3):iii-vi, 3-50. PubMed ID: 16330284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
